This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignees: Athena Neurosciences, Inc., Eli Lilly and Company, The Brigham and Women's Hospital, Inc.. Active years: 1998-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Vienna, AT (1998)
- Vienna, AU (2001)
Company Filing History:
2 out of 35 
2 out of 4,514 
1 out of 1,428 
Years Active: 1998-2001
Title: The Innovations of Michael G Schlossmacher
Introduction
Michael G Schlossmacher is a prominent inventor based in Vienna, Austria. He has made significant contributions to the field of neuroscience, particularly in the study of Alzheimer's disease. With a total of 3 patents, his work focuses on methods for identifying and measuring beta-amyloid peptides, which are crucial in understanding neurodegenerative conditions.
Latest Patents
Schlossmacher's latest patents include a method for identifying beta-amyloid peptide production inhibitors. This method involves administering a compound to a mammalian host to identify inhibitors of beta-amyloid peptide production. Another notable patent is related to methods and compositions for the detection of soluble beta-amyloid. This patent details the measurement of soluble beta-amyloid peptide in biological fluids at very low concentrations, typically ranging from 0.1 ng/ml to 10 ng/ml. The ability to measure beta-amyloid concentrations in animals or cultured cells is essential for drug screening, as elevated levels of beta-amyloid in body fluids are associated with conditions like Alzheimer's disease.
Career Highlights
Throughout his career, Schlossmacher has worked with notable companies such as Athena Neurosciences, Inc. and Eli Lilly and Company. His experience in these organizations has allowed him to contribute to significant advancements in the understanding and treatment of neurodegenerative diseases.
Collaborations
Schlossmacher has collaborated with esteemed colleagues in the field, including Dennis J Selkoe and Dale Bernard Schenk. These collaborations have further enhanced his research and innovations in the study of beta-amyloid peptides.
Conclusion
Michael G Schlossmacher's work has had a profound impact on the field of neuroscience, particularly in relation to Alzheimer's disease. His innovative patents and collaborations continue to pave the way for advancements in understanding and treating neurodegenerative conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile